Aer To Address Unmet Need In Mucus Plug-High COPD
Phase I To Start This Year
Executive Summary
The US biotech has closed a financing round aimed at advancing its novel mucolytic agent for a subtype of COPD with the hopes of tapping into a market of five million patients in the US alone.